 |
Bouliga
1ml 2ml 3ml 5ml
15mg/ml - 30mg/ml
Specification | Ophthalmic surgery | Joint injection | Anti adhesion |
Model No. | 1ml, 2ml, 3ml, 5ml, 10ml, 20ml, 50ml | ||
Concentration | 18mg/ml-30mg/ml | ||
Ingredient | Hyaluronic acid | ||
Needle | B&D | ||
Duration | 3-6 months | ||
Function | Lubrication and adhesion prevention | ||
1-5ml Sodium Hyaluronate Injections for Osteoarthritis represent a specialized therapeutic solution for managing joint pain and improving mobility in patients with osteoarthritis (OA). This pharmaceutical-grade sodium hyaluronate formulation is specifically designed for intra-articular administration, replenishing the depleted hyaluronic acid in degenerated joints to restore lubrication and cushioning. Unlike oral supplements that have limited joint penetration, these injections deliver high molecular weight hyaluronate directly to the synovial space, providing targeted relief.
Available in flexible 1–5ml dosages, the product allows for precise dosing based on joint size and severity of OA—from small joints like the thumb to larger weight-bearing joints such as the knee. Clinical studies demonstrate that a complete treatment course can reduce OA pain by 40–50% and improve joint function for 6–12 months in most patients. This sustained efficacy makes it a valuable non-pharmacological option for patients seeking alternatives to long-term NSAID use or considering joint replacement.
Manufactured to pharmaceutical standards, the sodium hyaluronate achieves 99.9% purity through advanced fermentation and purification processes. It contains less than 0.1EU/ml endotoxin and undetectable protein impurities, minimizing injection site reactions.
Featuring an average molecular weight of 1.5–2.5 MDa, the formulation closely matches the natural hyaluronic acid found in healthy synovial fluid. This high molecular weight contributes to superior viscoelastic properties, effectively restoring the joint's shock-absorbing capabilities.
Through a proprietary stabilization process, the hyaluronate resists enzymatic degradation in the joint space, maintaining therapeutic levels for 12–16 weeks after injection. This prolonged residence time reduces the need for frequent injections compared to lower molecular weight alternatives.
Each pre-filled syringe features a 21G precision needle and Luer-lock system for secure administration. The packaging includes a sterile field for preparation and a needle safety device to prevent accidental sticks, enhancing procedural safety.
Indicated for patients with Kellgren-Lawrence grade 2–3 OA who have not responded adequately to conservative treatments. Suitable for knee, hip, shoulder, and thumb base joints, with dosage adjusted based on joint volume (0.5–1ml for small joints, 2–5ml for large joints).
Administer following aseptic technique, with joint aspiration performed if significant effusion is present. For knee OA, the recommended approach is lateral or medial parapatellar, with the needle advanced to the synovial space. Inject slowly over 30–60 seconds to minimize discomfort.
The standard course consists of 3–5 weekly injections, with dosage per session ranging from 1ml (small joints) to 5ml (large joints). Many practitioners observe initial improvement after the second injection, with maximum effect developing 2–4 weeks after the final injection.
Advise patients to avoid strenuous activity and heavy weight-bearing for 48–72 hours post-injection. Mild swelling or discomfort can be managed with cold compresses (15 minutes hourly). Notify patients that full therapeutic effect may take 2–4 weeks to develop after the complete course.
It replenishes the hyaluronic acid in degenerated joints, restoring the synovial fluid's viscoelastic properties to improve lubrication and shock absorption. This mechanical effect reduces friction between joint surfaces while also supporting chondrocyte function and reducing inflammation.
Most commonly used for knee OA, but also effective for hip, shoulder, ankle, and thumb base osteoarthritis. Dosage adjusts based on joint size: 1ml for thumb, 2–3ml for ankle/shoulder, and 3–5ml for knee/hip joints.
Patients typically report reduced pain and improved mobility starting 2–4 weeks after completing the injection course. Maximum benefit occurs at 8–12 weeks, with results lasting 6–12 months depending on OA severity and joint location.
Mild injection site pain or swelling occurs in 3–5% of cases, resolving within 2–3 days. Serious adverse events (infection, severe inflammation) are extremely rare (<0.1%) when proper aseptic technique is followed. Contraindicated in joints with active infection or skin disease over the injection site.
While steroids provide faster pain relief (1–3 days), their effects last only 2–12 weeks and may accelerate cartilage breakdown with repeated use. Sodium hyaluronate works more gradually but provides longer-lasting benefits (6–12 months) with a favorable safety profile for repeated courses.
Specification | Ophthalmic surgery | Joint injection | Anti adhesion |
Model No. | 1ml, 2ml, 3ml, 5ml, 10ml, 20ml, 50ml | ||
Concentration | 18mg/ml-30mg/ml | ||
Ingredient | Hyaluronic acid | ||
Needle | B&D | ||
Duration | 3-6 months | ||
Function | Lubrication and adhesion prevention | ||
1-5ml Sodium Hyaluronate Injections for Osteoarthritis represent a specialized therapeutic solution for managing joint pain and improving mobility in patients with osteoarthritis (OA). This pharmaceutical-grade sodium hyaluronate formulation is specifically designed for intra-articular administration, replenishing the depleted hyaluronic acid in degenerated joints to restore lubrication and cushioning. Unlike oral supplements that have limited joint penetration, these injections deliver high molecular weight hyaluronate directly to the synovial space, providing targeted relief.
Available in flexible 1–5ml dosages, the product allows for precise dosing based on joint size and severity of OA—from small joints like the thumb to larger weight-bearing joints such as the knee. Clinical studies demonstrate that a complete treatment course can reduce OA pain by 40–50% and improve joint function for 6–12 months in most patients. This sustained efficacy makes it a valuable non-pharmacological option for patients seeking alternatives to long-term NSAID use or considering joint replacement.
Manufactured to pharmaceutical standards, the sodium hyaluronate achieves 99.9% purity through advanced fermentation and purification processes. It contains less than 0.1EU/ml endotoxin and undetectable protein impurities, minimizing injection site reactions.
Featuring an average molecular weight of 1.5–2.5 MDa, the formulation closely matches the natural hyaluronic acid found in healthy synovial fluid. This high molecular weight contributes to superior viscoelastic properties, effectively restoring the joint's shock-absorbing capabilities.
Through a proprietary stabilization process, the hyaluronate resists enzymatic degradation in the joint space, maintaining therapeutic levels for 12–16 weeks after injection. This prolonged residence time reduces the need for frequent injections compared to lower molecular weight alternatives.
Each pre-filled syringe features a 21G precision needle and Luer-lock system for secure administration. The packaging includes a sterile field for preparation and a needle safety device to prevent accidental sticks, enhancing procedural safety.
Indicated for patients with Kellgren-Lawrence grade 2–3 OA who have not responded adequately to conservative treatments. Suitable for knee, hip, shoulder, and thumb base joints, with dosage adjusted based on joint volume (0.5–1ml for small joints, 2–5ml for large joints).
Administer following aseptic technique, with joint aspiration performed if significant effusion is present. For knee OA, the recommended approach is lateral or medial parapatellar, with the needle advanced to the synovial space. Inject slowly over 30–60 seconds to minimize discomfort.
The standard course consists of 3–5 weekly injections, with dosage per session ranging from 1ml (small joints) to 5ml (large joints). Many practitioners observe initial improvement after the second injection, with maximum effect developing 2–4 weeks after the final injection.
Advise patients to avoid strenuous activity and heavy weight-bearing for 48–72 hours post-injection. Mild swelling or discomfort can be managed with cold compresses (15 minutes hourly). Notify patients that full therapeutic effect may take 2–4 weeks to develop after the complete course.
It replenishes the hyaluronic acid in degenerated joints, restoring the synovial fluid's viscoelastic properties to improve lubrication and shock absorption. This mechanical effect reduces friction between joint surfaces while also supporting chondrocyte function and reducing inflammation.
Most commonly used for knee OA, but also effective for hip, shoulder, ankle, and thumb base osteoarthritis. Dosage adjusts based on joint size: 1ml for thumb, 2–3ml for ankle/shoulder, and 3–5ml for knee/hip joints.
Patients typically report reduced pain and improved mobility starting 2–4 weeks after completing the injection course. Maximum benefit occurs at 8–12 weeks, with results lasting 6–12 months depending on OA severity and joint location.
Mild injection site pain or swelling occurs in 3–5% of cases, resolving within 2–3 days. Serious adverse events (infection, severe inflammation) are extremely rare (<0.1%) when proper aseptic technique is followed. Contraindicated in joints with active infection or skin disease over the injection site.
While steroids provide faster pain relief (1–3 days), their effects last only 2–12 weeks and may accelerate cartilage breakdown with repeated use. Sodium hyaluronate works more gradually but provides longer-lasting benefits (6–12 months) with a favorable safety profile for repeated courses.
